Li Zhang

Li Zhang

Auto-generated profile, based on publicly available information

Li Zhang

Peking University Biomedical Pioneering Innovation Center, Center for Reproductive Medicine Department of Obstetrics and Gynecology Third Hospital, Beijing 100191

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2026 in Protein & Cell
Verified
Journal Article
Open access
HXHaoling Xie
Haoling Xie
JLJingyi Li
Jingyi Li
LZLi Zhang
Li Zhang
XXXueqiang Xu
Xueqiang Xu
ZJZhenhuan Jiang
Zhenhuan Jiang
FTFuchou Tang
Fuchou Tang
Spermatogenesis is an intricately regulated epigenetic process, yet the exact chromatin dynamics during human meiosis and their systemic failure in non-obstructive azoospermia remain elusive due to the sparsity of single-cell epigenomic data in previous studies. Here, leveraging a high-quality scATAC-seq approach, we mapped over 810,000 cis-regulatory elements across human spermatogenesis. We uncovered a highly synchronized, wave-like activation of master transcription factor networks that precisely orchestrates meiotic progression. Crucially, we traced the dynamic process of opening and closing of chromatin states at meiotic DNA double-strand break hotspot regions at single-cell resolution, defining a transient epigenetic window where thousands of these predefined regions become specifically accessible. In NOA patients, this delicate architecture collapses, leading to severe spermatogenic arrest predominantly at the zygotene stage. We characterize this pathogenesis as the temporal dephasing and decoupling of the activities of master TFs. Furthermore, aberrantly reduced chromatin accessibility at DSB hotspot regions in NOA is potentially associated with defective DSB formation, accompanied by a two- to three-fold increase in sperm aneuploidy. Finally, we establish a functional paradigm for interpreting male infertility by linking non-coding GWAS variants (e.g., the MHC II locus) and rare point mutations to the disruption of cis-regulatory elements. Together, our study provides an unprecedented epigenetic roadmap of human spermatogenesis and redefines NOA pathogenesis from descriptive phenotypes to precise, network-level regulatory failures.

4 April 2025 in Journal of Advanced Research
Verified
Journal Article
Open access
YSYujiao Sun
Yujiao Sun
SSShihao Shao
Shihao Shao
JHJiangwei Huang
Jiangwei Huang
HSHao Shi
Hao Shi
LYLiying Yan
Liying Yan
LZLi Zhang
Li Zhang
The difficulty of identifying human round spermatids (hRSs) has impeded applications of the human round spermatid injection (ROSI) technique. RSs can be accurately screened through flow cytometric analysis utilizing the Hoechst fluorescence profile reflecting DNA, but this method is not suitable for isolating hRSs due to the toxicity associated with Hoechst staining. To evaluate the capacity of a deep learning model grounded in a cascade mask region-based convolutional neural network (R-CNN) for the noninvasive and accurate identification of hRSs. In this study, we presented the development and validation of a deep learning model for identifying hRSs through the analysis of 3457 optical light microscope images of sorted hRSs obtained via flow cytometric analysis. The model's accuracy and specificity were evaluated by calculating the mean average precision (mAP). Furthermore, a double-blind experiment was conducted to access the reliability of the proposed model in accurately identifying hRSs. It detected the expression of protamine (PRM1) and/or peanut lectin (PNA), which are established markers for RSs. Our deep learning-based model demonstrated a high precision, achieving a mAP of over 0.80 for isolating hRSs in test datasets. The expression of PRM1 and/or PNA was observed in all cells noninvasively selected by our AI model during an independent double-blind test. This phenomenon confirmed the accuracy and effectiveness of the proposed model. The model's capability for noninvasive and accurate isolation of hRSs among spermatogenic cells highlighted its robustness and generalizability for clinical applications. The deep learning AI model based on a cascade R-CNN has the ability to accurately identify hRSs among spermatogenic cells. The application of this noninvasive method, which requires no additional procedures in clinical practice, is able to facilitate the widespread implementation of ROSI technique. Therefore, it can provide patients with spermatogenic arrest the opportunity to become biological fathers.

9 October 2024 in Human Reproduction Open
Verified
Journal Article
Open access
PDF file
YFYangyi Fang
Yangyi Fang
ZZZhe Zhang
Zhe Zhang
YCYinchu Cheng
Yinchu Cheng
ZHZhigao Huang
Zhigao Huang
JPJiayuan Pan
Jiayuan Pan
KHKai Hong
Kai Hong
STUDY QUESTION: Which independent factors influence ICSI outcomes in patients with complete azoospermia factor c (AZFc) microdeletions? SUMMARY ANSWER: In patients with complete AZFc microdeletions, the sperm source, male LH, the type of infertility in women, and maternal age are the independent factors associated with ICSI outcomes. WHAT IS KNOWN ALREADY: AZF microdeletions are the second most prevalent factor contributing to infertility in men, with AZFc microdeletions being the most frequently affected locus, accounting for 60–70% of all cases. The primary clinical phenotypes are oligoasthenozoospermia and azoospermia in patients with complete AZFc microdeletions. These patients can achieve paternity through ICSI using either testicular (T-S) or ejaculated (E-S) spermatozoa. With aging in men with AZFc microdeletions, oligoasthenozoospermia or severe oligozoospermia may gradually progress to azoospermia. STUDY DESIGN, SIZE, DURATION: In this retrospective cohort study, the independent factors associated with the outcomes of 634 ICSI cycles in 634 couples with the transfer of 1005 embryos between February 2015 and December 2023 were evaluated. The analysis included 398 ICSI cycles in 398 couples using E-S and 236 ICSI cycles in 236 couples using T-S; all men had complete AZFc microdeletions. PARTICIPANTS/MATERIALS, SETTING, METHODS: The inclusion criteria were as follows: (i) men had complete AZFc microdeletions and (ii) the couple underwent ICSI treatment using T-S or E-S. The exclusion criteria were as follows: (i) cycles involving frozen–thawed oocytes; (ii) cycles in which all fresh embryos were frozen and not transferred; (iii) cycles lost to follow-up; and (iv) multiple ICSI cycles, apart from the first cycle for each couple. The primary outcome was the cumulative live birth rate per ICSI cycle, whereas the secondary outcomes were the clinical pregnancy rate per ICSI cycle, fertilization rate, and the no-embryo-suitable-for-transfer cycle rate (NESTR). Moreover, the maternal and neonatal outcomes were analyzed. Continuous variables showing non-normal distributions were expressed as median and interquartile range and were analyzed using the Kruskal–Wallis test. Categorical variables were expressed as percentages and were analyzed using the χ2 or Fisher’s exact test. Linear and logistic regression models were constructed to assess the independent factors associated with ICSI outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: The T-S group exhibited inferior ICSI outcomes than the E-S group, marked by significantly reduced rates of cumulative live birth, clinical pregnancy, fertilization, high-quality embryos, blastocyst formation, and implantation, with higher NESTRs. However, the miscarriage rate and neonatal outcomes did not significantly differ between the groups. Multivariate linear regression analysis demonstrated that reduced fertilization rates were significantly associated with T-S use (adjusted β, −0.281; 95% CI, −0.332 to −0.229). Multivariate logistic regression demonstrated that increased NESTRs were significantly associated with T-S use (adjusted odds ratio (OR), 4.204; 95% CI, 2.340–7.691), along with uterine anomaly in women (adjusted OR, 2.853; 95% CI, 1.053–7.718), infertility in women with multiple etiologies (adjusted OR, 11.118; 95% CI, 2.034–66.508), and advanced maternal age (adjusted OR, 1.138; 95% CI, 1.029–1.263). The use of T-S (adjusted OR, 0.318; 95% CI, 0.188–0.528), uterine anomaly in women (adjusted OR, 0.263; 95% CI, 0.058–0.852), and increased maternal age (adjusted OR, 0.877; 95% CI, 0.801–0.958) were also associated with decreased clinical pregnancy rates per ICSI cycle. Likewise, lower cumulative live birth rates were associated with T-S use (adjusted OR, 0.273; 95% CI, 0.156–0.468), male LH levels (adjusted OR, 0.912; 95% CI, 0.837–0.990), uterine anomaly (adjusted OR, 0.101; 95% CI, 0.005–0.529), and increased maternal age (adjusted OR, 0.873; 95% CI, 0.795–0.958). No significant differences were observed in the maternal and neonatal outcomes between both groups. LIMITATIONS, REASONS FOR CAUTION: The study was based on a single-center, retrospective cohort design. The molecular diagnosis of AZFc microdeletions was reliant on loci sY254 and sY255 according to the European Academy of Andrology and European Molecular Genetics Quality Network guidelines. While our findings were based on the clinical phenotypes and laboratory parameters, the abnormalities in the genetic profiles of spermatogenesis and early embryonic development in patients between the T-S and E-S groups have not yet been elucidated. WIDER IMPLICATIONS OF THE FINDINGS: Our results offer important insights into the independent factors that influence ICSI outcomes in patients with complete AZFc microdeletions. ICSI using E-S is a more favorable therapeutic option for younger patients with AZFc microdeletions and with sperm present in their ejaculate. This study highlights a new direction to investigate the molecular and phenotypic differences between the T-S and E-S groups, which may contribute to the diagnosis and treatment of complete AZFc microdeletions. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by Capital’s Funds for Health Improvement and Research (2022-2-4094), Beijing Natural Science Foundation (7232203, 7242164), National Key Research and Development Program (2021YFC2700200, 2023YFC2705600), National Natural Science Foundation of China (82301889), Peking University Third Hospital Innovation Transformation Fund (BYSYZHKC2023103), Peking University Third Hospital Clinical Cohort Construction Project (BYSYDL2023016), and Young Elite Scientists Sponsorship Program by CAST (2023QNRC001). None of the authors have any competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.